Access to Gene Therapies for Rare Diseases: Barry Byrne, MD, PhD

“Access is a really important issue in the rare disease community, because we're representing patients worldwide... we've spent a considerable effort on understanding manufacturing technology that will lower costs and improve access... That, hopefully, will benefit patients in areas where third party payers don't have the same resources as in the US and Europe. We look forward to making that available to a wider community.”